治療心絞痛 抗血小板口服 Carotid endarterectomy.
Cerebrovascular accident.
Cerebrovascular accident, Secondary; Prophylaxis.
Coronary artery bypass graft.
Disorder of joint of spine.
Fever.
Generalized aches and pains.
Headache.
Migraine.
Myocardial infarction.
Myocardial infarction, In patients with chronic coronary artery disease; Prophylaxis.
Myocardial infarction, Primary; Prophylaxis.
Osteoarthritis.
Pain.
Percutaneous coronary intervention.
Rheumatoid arthritis.
Stable angina, chronic.
Systemic lupus erythematosus, Arthritis and Pleurisy.
Transient ischemic attack; Treatment and Prophylaxis.
Unstable angina.

Aspirin is a more potent inhibitor of both prostaglandin synthesis and platelet aggregation than its other salicylic derivatives due to the acetyl group on the aspirin molecule, which irreversibly inactivates cyclooxygenase via acetylation . This prevents the conversion of arachidonic acid to thromboxane A(2). Platelet aggregation is inhibited for their lifespan of 7 to 10 days.

Absorption:
Bioavailability, Oral, immediate release: Well and completely absorbed
Bioavailability, Oral, enteric coated: Erratically absorbed .
Distribution:
Vd: 150 [32]to 170 mL/kg .
Metabolism:
Aspirin, Hepatic; hydrolysis
Excretion:
Renal: 10% (salicylic acid), 75% (salicyluric acid), 10% (phenolic glucuronide), 5% (acyl glucuronide)
Dialyzable: yes (hemodialysis); yes (peritoneal dialysis)
Elimination Half Life:
Aspirin, 20 to 60 minutes

Hypersensitivity to NSAIDs
Syndrome of asthma, rhinitis, and nasal polyps; severe urticaria, angioedema, or bronchospasm may occur .

Fetal risk cannot be ruled out. (TH)

Drugs that have been associated with significant effects on some nursing infants and should be given to nursing mothers with caution.(AAP)
Avoid breastfeeding.(WHO)
Infant risk cannot be ruled out.(MDX)

Serious:
Gastrointestinal: Gastrointestinal ulcer
Hematologic: Hemorrhage
Ophthalmic: Exudative age-related macular degeneration
Otic: Tinnitus
Respiratory: Bronchospasm
Other: Angioedema, Reye's syndrome

Angina, chronic:
75 to 325 mg ORALLY once a day
Myocardial infarction:
Initial, chew 162 to 325 mg orally immediately at symptom onset .
Myocardial infarction, Prophylaxis:
75 to 100 mg/day , continued indefinitely in almost all patients (guideline dosage)
Dual antiplatelet therapy, clopidogrel for a minimum of 14 days and ideally at least 12 months; may continue beyond 12 months in select patients
Dual antiplatelet therapy (pci with bare metal or DES), clopidogrel OR ticagrelor OR prasugrel for at least 12 months; may consider discontinuation after 6 months in patient with DES and high bleeding risk
Dual antiplatelet therapy (undergoing CABG), resume P2Y12 inhibitor after CABG to complete 12 months of therapy following acute coronary syndrome (guideline dosage)
Atrial fibrillation - Thromboembolic disorder; Prophylaxis:
75 to 325 mg ORALLY daily
Transient ischemic attack; Treatment and Prophylaxis:
initial, 160 to 325 mg ORALLY within 48 hours of event
(secondary prophylaxis) 75 to 100 mg ORALLY daily
Cerebrovascular accident:
160 to 325 mg ORALLY within 48 hours of event, followed by secondary prophylaxis with 75 to 100 mg daily.

Kawasaki disease:
80 to 100 mg/kg/day divided every 6 hours for up to 14 days (until fever resolves for at least 48 hours); then decrease dose to 1 to 5 mg/kg/day once daily.

Renal impairment, severe (GFR less than 10 mL/min): Avoid use

Hepatic impairment, severe: Avoid use